KCNH5 and glioblastoma: In neuron-GBM interactions, the engineered peptide K90-114TAT disrupts the EAG2–Kvβ2 potassium channel complex, effectively attenuating tumor growth and invasion by targeting a key pathway in glioblastoma progression [106].